Dr. Steven 'Steev' C. Sutton received his B.S. Pharmacy from Massachusetts College of Pharmacy, Boston, and his Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo. Dr. Sutton, a Rho Chi member, worked as a retail pharmacist in Harvard Square and Lowell, MA before returning to school. After graduate school he joined the General Pharmaceutics Group, Ciba-Geigy (now Novartis), for several years. Then Dr. Sutton and his family moved to Lawrence, KS for a stint at INTERx Research Corporation, (founded by Takeru Higuchi, the 'father of physical pharmacy', and a subsidary of Merck & Co).
Dr. Sutton then moved back to New England and joined the Groton, CT Lab of Pfizer in what was then called the Pharmaceutical R&D Department. In 2009, he embarked on his second career of teaching at the College of Pharmacy at the University of New England, Portland, Maine.
Dr. Sutton has been active in his professional organization the American Association of Pharmaceutical Scientists (AAPS). For example, he founded the AAPS Oral Absorption Focus Group, and was a founding member of both the Hudson Valley and Kansas City Pharmaceutics Discussion Groups. He served as General Chair of the AAPS Midwest Regional Meeting, as well as organized numerous national meeting symposia over the years. He is also a member of the editorial board of the AAPS PharmSciTech and The AAPS Journal. Dr. Sutton is a research Fellow of the American Association of Pharmaceutical Scientists, and a Fellow of the American Academy of Veterinary Pharmacology and Therapeutics. Dr. Sutton has a visiting scientist status at MCPHS, College of Pharmacy, and SUNY at Buffalo, College of Pharmacy. Previously, he also held adjunct professor appointments at the School of Pharmaceutical Sciences, Kansas University (KU), Lawrence, the School of Pharmacy, University of Missouri-Kansas City (UMKC) and at the University of Connecticut, School of Pharmacy. At KU and UMKC, he served as a member on graduate students' research committees.
Dr. Sutton has authored or co-authored about 130 book chapters, abstracts of work in progress, invited presentations and patents.
Dr. Sutton met his wife, Kimberly in graduate school. They have three children: Brenton, an employee of Origene, Inc. (Rockville, MD), Alexander an Analyst at BCG, Boston and Katherine, who recently started working for Purina in Australia.
Dr Sutton's personal interests include hiking, fine woodworking and trying to grow tomatos.
State University of New York at Buffalo
Massachusetts College of Pharmacy
Board Certifications and Licenses
Pharmacy: MA, NY
A Farnham, SH Stafford, SC Sutton: Impact of Dose on Amount of Polystyrene Nanoparticles Translocated Across Caco-2 Cell Monolayers, AAPS NERDG Annual Meeting, Farmington, CT, April 20, 2017.
A Farnham, SC Sutton: An HT29 Cell Monolayer Model to Investigate the Cumulative Genotoxic Effects of POPs and Nanoparticles, AAPS NERDG Annual Meeting, Farmington, CT. April 19, 2016.
Duong, S. and S. C. Sutton: Predicting the Physiologically Relevant Precipitation Rate of Weakly Basic Drugs Using Potentiometric Titration. AAPS National Meeting, San Antonio, TX, AAPS, 2013.
Determine the mechanisms by which persistent organic pollutants (POPs) associated with micron-sized fragments of ocean-sourced plastic find their way into the food web.
Investigate the nuances of weakly basic drugs (WBD) that predispose them to precipitate in the intestine after oral administration. The goals of this research are 1) to predict in silico whether a WBD will precipitate in vivo.
Sutton, S. C., R. Nause and K. Gandelman (2017). "The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption." The AAPS Journal: 1-7 (published online 20 March 2017
Thombre, A.G., W.B. Caldwell, D.T. Friesen, S.B. McCray, and S.C. Sutton, Solid Nanocrystalline Dispersions of Ziprasidone with Enhanced Bioavailability in the Fasted State. Molecular Pharmaceutics, 2012, 9:3526-3534
Claxton, R., Endrenyi, L., Lucas, A., Martinez, M. & Sutton, S. Estimating product bioequivalence for highly variable veterinary drugs. J Vet Pharmacol Therap, 2012, 35:11-16.
Steven C. Sutton, The Use of Gastrointestinal Intubation Studies For Controlled Release Development. British Journal of Clinical Pharmacology, 2009. 68(3): p. 342-354.
Sutton, S.C., Role of Physiological Intestinal Water in Oral Absorption. The AAPS Journal, 2009. 11(2): p. 277-285
Other Scholarly Activity
Sutton, S. C. (2017). Chapter 3. Drug Administration and Drug Absorption. Basic Pharmacokinetics and Pharmacodynamics. S. Rosenbaum. Hoboken, NJ, Wiley: 35-70.
Sutton, S. C. (2017). Chapter 9. Pharmacokinetics of Extravascular Drug Administration. Basic Pharmacokinetics and Pharmacodynamics. S. Rosenbaum. Hoboken, NJ, Wiley: 201-224
Sutton, S.C: Chapter 6: “Biopharmaceutics and veterinary drug delivery”, In: Animal Health Drug Delivery, Michael Rathbone (Ed), Controlled Release Society, The Springer Publishing Company, New York 2013
Sutton, S.C: Chapter 4: “Anatomy and physiology of the companion animal”, In: Animal Health Drug Delivery, Michael Rathbone (Ed), Controlled Release Society, The Springer Publishing Company, New York 2013
Jaymin Shah, Steve Sutton, Susan Way, Gayle Brazeau: “Parenteral Formulations: Local Injection Site Reaction and Muscle Tolerance”, In: Encyclopedia of Pharmaceutical Technology Third Edition, James Swarbrick (ed) Informa Healthcare USA, Inc., New York 2013
Sutton, S.C., P. Smith: Chapter 3. Animals Suitable for Modeling Controlled Release, In: “Oral Controlled Release”, Clive Wilson, Brigitte Skalsky & Patrick Crowley (eds), Controlled Release Society, The Springer Publishing Company, New York, 2011
UNE Minigrant: “Physical-chemical characterization of fluorescent polystyrene nanoparticles after incubation in cell culture and digestive media”. Jun 2017-May 2018 ($3,846).
Maine INBRE RRC grant: Analysis of polycyclic-aromatic hydrocarbons by GCMS. 2015-16 ($1490.00).
UNE Minigrant: “Studies to determine the oral bioavailability of POPs from microplastic in mussels” Co-Investigator: Stephan Zeeman. Jun 2013-May 2014 ($7,800).
FDA: Development of FDA Reviewer Training Module "Biophysical Foundation of Pharmacokinetics and Biopharmaceutics" (NIPTE (PI), Rosemont, IL). 2013-2014 ($40,000).
Invited Plenary Presentation
Sutton, SC. Interspecies intestinal differences and impact on oral dosage forms for animal health” to be presented at the joint CRS/AAPS workshop “Animal Health Drug R&D: Formulation, Delivery and Development to Market”, November 1-2, 2014, in San Diego
Sutton, SC. The anatomy & physiology of interspecies’ biopharmaceutics, presented at the “Interspecies clinical pharmacology dosing concepts” mini-symposia, at the 2014 Annual Meeting of the Controlled Release Society, July 13-16, 2014, in Chicago
Sutton, SC. Predictive Animal Models for Assessing Long-Acting Formulations for Human and Animal Health, presented at the Inaugural Controlled and Modified Drug Release Conference in Philadelphia, PA on May 7-8, 201
Sutton, SC. Critical Features of Solubility and Permeability that can Limit the Food Effect, presented at the 2nd annual Drug Formulation & Bioavailability – West Coast, in San Diego, CA, on June 2-3, 2014
Sutton, S. C.: Biopharmaceutics and Pharmacokinetics of the Food Effect, presented at the Roundtable: When Food Impacts Oral Drug Exposure: The Nature and Study of the Food Effect. AAPS National Meeting, San Antonio, Nov., 2013.
Sutton SC. Utilizing in silico, in vitro and preclinical methods to optimize your clinical prediction from biopharmaceutic modeling. ExlPharma’s 2nd Enhancing Drug Bioavailability and Solubility Conference, Boston, MA January, 2013